IKT (Inhibikase Therapeutics) Long-Term Capital Lease Obligation : $0.03 Mil (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Inhibikase Therapeutics Long-Term Capital Lease Obligation?

Inhibikase Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.03 Mil.

Inhibikase Therapeutics's quarterly Long-Term Capital Lease Obligation declined from Dec. 2023 ($0.09 Mil) to Mar. 2024 ($0.06 Mil) and declined from Mar. 2024 ($0.06 Mil) to Jun. 2024 ($0.03 Mil).

Inhibikase Therapeutics's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.21 Mil) but then declined from Dec. 2022 ($0.21 Mil) to Dec. 2023 ($0.09 Mil).

Inhibikase Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Inhibikase Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibikase Therapeutics Long-Term Capital Lease Obligation Chart

Inhibikase Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.21

0.09

Inhibikase Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.15	0.12	0.09	0.06	0.03

Inhibikase Therapeutics (NAS:IKT) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Inhibikase Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Inhibikase Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibikase Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibikase Therapeutics Inc (NAS:IKT) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

3350 Riverwood Parkway SE, Suite 1900, Atlanta, GA, USA, 30339

Website

https://www.inhibikase.com

Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease.

Executives

Paul C Grint	director	7757 DOUGHILL COURT, SAN DIEGO CA 92127
Dennis N Berman	director	9605 SCRANTON RD, STE 240, SAN DIEGO CA 92121
Roy Lester Freeman	director	256 SUMMIT AVE, BROOKLINE MA 02446
Gisele Dion	director	C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Milton H. Werner	director, 10 percent owner, officer: President and CEO	3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339
Joseph Frattaroli	officer: Cheif Financial Officer
Elizabeth G. O'farrell	director	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Daniel Kalman	10 percent owner	3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339